Abstract: Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients. The most frequent clinically relevant mechanisms that change imatinib sensitivity in BCR-ABL-transformed cells are mutations within the Abl kinase domain, affecting several of its properties. Crystal structure analysis of the Abl-imatinib complex has proven helpful in identifying potential critical residues that hinder interactions of imatinib with mutated Abl. This has led to the development of a second generation of targeted therapies such as nilotinib and dasatinib, already in phase II clinical trials or SKI-606 and MK-0457 in phase I trials. In this review, we discuss the activity of nilotinib, developed by Novartis using a rational drug design strategy in which imatinib served as the lead compound. Preliminary studies demonstrated that nilotinib has more effi cacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profi le and clinical effi cacy in all phases of CML.
Introduction
In the last 5 years many clinical studies have demonstrated that imatinib, the fi rst tyrosine kinase inhibitor introduced in the treatment of chronic myeloid leukemia (CML) (Olsson-Stromberg et al) has high level of activity, low toxicity, and ongoing durability (Druker et al 2001; O'Brien and Deininger 2003; Baccarani et al 2004; Kantarjian et al 2004) . Its effi cacy is mainly observed in newly diagnosed patients with chronic phase CML, where complete hematological and cytogenetic responses where achieved in about 98% and in more than 80% of cases, respectively (Hughes et al 2003; Muller et al 2003; Kantarjian et al 2006c) . The fi ndings of the 5-year update of the International Randomised Study of Interferon versus STI571 (IRIS) comparing the effi cacy of imatinib 400 mg/day with interferon-alpha (IFNα) + ara-c in newly diagnosed patients with chronic phase CML showed an estimated rate of complete cytogenetic response (CCR) of 87% and an overall survival rate of 89% at 60 months . With similar follow-up for patients initially studied in "late chronic phase" disease with intolerance or failure during prior IFN, CCR was achieved in 53%, refl ecting the remarkable ability of imatinib to salvage such patients (Iacobucci et al 2006) . Although the rates of progression for patients with chronic phase CML treated with imatinib remain low, a subset of patients develops resistance to this drug. The most common mechanism of resistance is the expansion of a clone of leukemic cells with a mutation in the kinase domain of Bcr-Abl (Branford et al 2002; Shah 2005; Soverini et al 2005; Branford and Hughes 2006) . This mutant clone is partially or totally imatinib resistant because of the reduced capacity to imatinib to bind to the mutant Bcr-Abl protein. Therapeutic options in cases of imatinib resistance include increasing the dose of imatinib, switching to a second generation Abl kinase inhibitor and proceeding to an allogenic stem cell transplant. In this review, we focus on the characterization of nilotinib, a novel, oral tyrosine kinase inhibitor developed from its parent compound, imatinib, and we discuss its current status in clinical trials.
Mechanisms of imatinib resistance
Depending on the time of onset, two categories of resistance can be distinguished: if there is no response after initial treatment, resistance is described as primary or intrinsic, in contrast, secondary or extrinsic resistance refers to loss of a previously established response (Hochhaus 2003) . The rate of all progression events, including hematologic and cytogenetic relapse within chronic phase and transformation to advanced phase is 18% after a median of 5 years (Mauro 2006) . Although the molecular mechanisms responsible for the rare cases of primary resistance remain poor, the mechanisms of secondary resistance are largely understood. In the majority of cases, resistance is caused by reactivation of BCR-ABL tyrosine kinase activity due to the emergence of specifi c point mutations within several critical regions of the Abl kinase domain (Hochhaus et al 2002; Shah et al 2002; Branford et al 2003; Soverini et al 2006) . Such mutations impair imatinib binding either by affecting critical contact residues or by inducing a BCR-ABL conformation to which imatinib is unable to bind. More than 40 different point mutations encoding for distinct single amino acid substitutions in the Bcr-Abl kinase domain have been identifi ed in relapsed CML patients. Different mutants seem to have different degrees of resistance to imatinib: in vitro data indicate that while some mutations might be overcome by dose escalation (O'Hare et al 2006), others confer a highly resistant phenotype, thereby suggesting withdrawal of imatinib in favor of alternative therapeutic strategies. Indeed, since resistance often coincides with reactivation of the kinase activity within the leukemic clone, either Bcr-Abl itself or Bcr-Abl-triggered downstream signaling pathways remain good targets for molecular therapy.
Mechanisms of imatinib resistance that do not involve ABL mutations but are clinically relevant include amplification of the BCR-ABL fusion gene, transcriptional overexpression of Bcr-Abl, increased multi-drug resistance (MDR) activity (Marull and Rochat 2006; White et al 2006) , cytogenetic progression, or possible the involvement of other kinases including members of the Src family (Cowan-Jacob et al 2004; Krause and Van Etten 2005) . In patients who achieve a deep reduction in leukemic-cell burden, BCR-ABL transcripts rarely become undetectable and the disease recurs in most of these patients if imatinib is discontinued. This persistence of a molecularly detectable leukemic population is due to CML "stem cell resistance", based in the ability of CML progenitors to exchange between a cycling and resting or "quiescent" state, the latter associated with minimal or no BCR-ABL expression and resulting lack of effect of Abl kinase inhibitors (Goldman and Gordon 2006) .
Looking behind imatinib: nilotinib, a novel inhibitor of BCR-ABL
The emergence of imatinib resistance has stimulated the development of new kinase inhibitors that are able to overcome or prevent the development of mechanisms of failure and ultimately eliminate all evidence of disease. Two of these inhibitors are in phase II trials: dasatinib (formerly BMS-354825, Spricel ® ) ( Nilotinib was developed by researchers at Novartis Pharmaceuticals using a rational drug design strategy based on the replacement of the metylpiperazinyl group of imatinib and optimization of drug-like properties ( Figure 1 ).
Like imatinib, nilotinib does not inhibit Src kinase and binds only to the inactive conformation of Bcr-Abl, with P-loop folding over the ATP-binding site, and the activationloop blocking the substrate binding site, to disrupt the ATP-phosphate-binding site and inhibit the catalytic activity of the enzyme (Weisberg et al 2006) . Nilotinib makes 4 hydrogen-bond interactions with the Abl kinase domain, involving the pyridyl-N and the backbone-NH of Met318, the aniline-NH and the side chain hydroxyl of Thr315, the amido-NH and side chain carboxylate of Glu286, as well as the amido-C== O of Asp381 and a fl uorine atom in the trifl uoromethyl group of nilotinib (Weisberg et al 2006) . This close interaction made changes in the core of imatinib prohibitive. The improvement in binding affi nity for Bcr-Abl maintains the ability to inhibit also Kit and PDGFR, but with less affi nity of imatinib (Bcr-Abl Ͼ PDGFR Ͼ Kit).
Preclinical studies
Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL-dependent cells derived Nilotinib does not inhibit T315I (also resistant to imatinib and dasatinib), due to the loss of the hydroxyl side chain and the introduction of the methyl group of the isoleucine in the "gatekeeper" region of the ATP binding site, which inhibits binding (Pricl et al 2005) . On the other hand, M351I is more sensitive to nilotinib than would be predicted. This residue makes close contact with imatinib, but not with nilotinib, due to the differences in their chemical structure. Therefore, M351I affects the binding of imatinib, but has little effect on the binding of nilotinib (O'Hare et al 2005) (Table 1) . In vivo studies demonstrated that nilotinib increased survival in mouse models with native Bcr-Abl and imatinib-resistant Bcr-Abl . Nilotinib is also approximately 30-40 times more potent than imatinib in inhibiting the proliferation of p190 Bcr-Abl -expressing Ph-positive ALL cell lines and it is also consistently (more than 20 times) more potent than imatinib in inhibiting phosphorylation of p190 Bcr-Abl kinase in these cell lines .
Phase I study
In a dose-escalating phase I study (Kantarjian et al 2006a) , nilotinib was administered orally to 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) according to the following dosing schedule: 50 mg (7 patients), 100 mg (7), 200 mg (10), 400 mg (10), 600 mg (6), 800 mg (19), and 1200 mg (10) or to receive 400 mg twice daily (32) or 600 mg twice daily (18). Plasma level saturation was observed at more than 400mg/day. Among 119 patients, 17 were in chronic phase disease, 56 in accelerated phase (10 with clonal evolution only), 24 in myeloid blast phase, 9 in lymphoid blast phase, and 13 had Ph-positive ALL. Signifi cant clinical activity was identifi ed in all CML phases. Overall, of 33 patients with the blastic phase, 13 had a hematologic response to nilotinib (39%) and 9 patients (27%) had a cytogenetic response, 6 of whom had a major cytogenetic response (Ph-positive cells in metaphase, Յ35%). Of 46 patients with accelerated-phase CML (excluding those with clonal evolution only), 33 had a hematologic response and 22 had a cytogenetic response; 9 of these responses were major. Among the 10 patients who had clonal evolution as the only feature of the accelerated phase of CML, 5 had active disease and 5 were in complete hematologic remission. All 5 patients with clonal evolution and hematologic disease had a complete hematologic response; 6 of 10 had a major cytogenetic response. Among 17 patients with the chronic phase of disease, 11 of 12 patients with active disease have had a complete hematologic remission. There were cytogenetic responses in 9 of 17 patients who could be evaluated, including 6 responses that were complete. One of 10 patients with Ph-positive ALL (hematologic relapse) had a partial hematologic response, and 1 of 3 patients with Ph-positive ALL and persistent molecular signs of ALL had a complete molecular remission (Table 2) . Response rates to nilotinib were similar in patients with and those without BCR-ABL mutations. Two patients with a mutation of T315I did not have a response to nilotinib, as predicted from preclinical studies.
The treatment was well tolerated. Most frequent grade 3-4 adverse events were hematologic, with thrombocytopenia and neutropenia seen in 20% and 12%, respectively. Other adverse events were less frequent and were primarily grade 1-2. Neutropenia and indirect self-limited reversible hyperbilirubinemia were observed mostly at the dose of 600 mg twice daily. A nilotinib dose of 400 mg twice daily was selected for the phase II studies based on effi cacy and long-term side effects (Jabbour et al 2006) . Nilotinib prolongs the QTcF interval in some patients. One unexplained sudden death was reported beyond the follow-up time analysis (Kantarjian et al 2006a) . This fi nding indicates the need for careful monitoring for cardiac events and arrhythmias in all patients who are receiving nilotinib and a strict avoidance of medications that may prolong the QTcF interval.
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Phase II studies
The phase II study was designated to evaluate the safety and effi cacy, as defi ned by hematologic (normalization of white blood cell counts) and cytogenetic (reduction or elimination of the Ph+ chromosome) response rates of nilotinib administered to imatinib-resistant or intolerant patients with Ph+ CML in chronic phase, accelerated phase, blastic phase and Ph-positive ALL. The 316 chronic-phase patients in the phase II study were heavily pre-treated for Ph+ CML, with a signifi cant majority (72%) having received at least 600 mg of imatinib as well as having been treated earlier with interferon (65%) and hydroxyurea (83%).
Among 279 assessable patients (ie, those patients with at least six months of follow up) with chronic-phase disease, major cytogenetic response was observed in 145 (52%) of which 96 (34%) were complete. Complete hematologic response was reported in 137 (74%) of 185 assessable patients. In patients with at least 10 months follow-up, the median time to cytogenetic response was 2.8 months (range 1-11), and the median time to complete hematologic response was 1.0 (range 1-8) months le Coutre et al 2006) .
Among 64 patients with accelerated-phase disease, major cytogenetic response was observed after at least 8 months follow-up in 23 patients (36%), of which 14 (22%) were complete. Confi rmed hematologic response occurred in 38 (59%), of which 15 (23%) were complete. The median time to cytogenetic response was 2.0 months (range 1-8), and the median time to complete hematologic response was 1.0 (range 1-3) months (Kantarjian et al 2006b) .
Preliminary data have also been presented for 96 blast phase and 34 Ph-positive ALL patients. Complete hematological response was reported in 12 (13%) blast phase patients, marrow response in 6 (6%), return to chronic phase and stable disease in 17 (18%) patient each. Complete responses were reported in 2 (6%) Ph+ ALL patients (1 relapsed/refractory and 1 with minimal residual disease) (Table 3) (Ottmann et al 2006) . Nilotinib: a new hope for CML
The phase II study showed an acceptable tolerability profi le with a low incidence of events related to fl uid retention such as edema, a side effect common with other tyrosine kinase inhibitors. The most frequent Grade 3 or 4 adverse events were primarily hematological in nature and include neutropenia and thrombocytepenia. Elevations were seen in bilirubin, liver function tests, lipase enzymes, and blood sugar, which were mostly transient and resolved over time. These cases were easily managed and rarely led to discontinuation. Pancreatitis was reported in less than 1% of cases. The study also showed virtually no non-hematologic cross-intolerance between imatinib and nilotinib (cross-intolerance occurs when patients cannot tolerate two different drugs because of the same side effects). Causes of non-hematologic intolerance to imatinib, which occurred in 95 patients, included Grade 3 or 4 rash/skin toxicity, fl uid retention, gastrointestinal intolerance, liver toxicity, and myalgia/arthralgia. When treated with nilotinib, none of these patients experienced severe rash/skin toxicity, fluid retention or myalgia/ arthralgia. One patient each experienced severe gastrointestinal intolerance and liver toxicity. Further follow-up of the phase II studies is ongoing.
Nilotinib as fi rst-line therapy
Based on Phase II experience, a study of nilotinib as fi rst line therapy for patients with CML in early chronic phase has been started with the objective to improve the overall molecular response and to achieve responses earlier since early achievement of response has been correlated with improved long-term outcome. The preliminary data in 14 patients treated suggest that indeed the higher potency is translating into better responses, with 100% of patients in complete hematologic response after 3 months of therapy, and 100% of patients in complete cytogenetic response within 6 months. A major molecular response was achieved in 54% by 6 months. These responses appeared to be more rapid than observed with imatinib 800 mg daily (Jabbour et al 2006) .
In addition, considering the effi cacy of nilotinib after failure to imatinib, there is interest in exploring earlier intervention in patients who have not met the criteria for failure but have a suboptimal response as defi ned by the recommendations of a panel of CML experts (Baccarani et al 2006) .
Future strategies
There is an urgent need for the development of compounds active against the T315I-Bcr-Abl mutant because it might drive the majority of cases who acquire resistance to novel second-generation inhibitors. The T315I is responsible for approximately 15% of the cases of relapse in CML and Ph+ ALL patients on imatinib therapy. Structural analyses indicate that the substitution of threonine with isoleucine at residue 315 eliminates a crucial hydrogen-bonding interaction and introduces a steric clash which abrogates binding and effective inhibition of Bcr-Abl by imatinib as well as by several novel inhibitors (Pricl et al 2005) . A different approach to tyrosine kinase inhibition is to design inhibitors binding regions of Bcr-Abl other than the ATP binding pocket. This is the case of ON012380 (Gumireddy et al 2005) , which binds to the substrate binding site. ON01910 is a similar agent that also inhibits Plk1, a kinase that plays a critical role in cell cycle progression. Adaphostin is a non-ATP competitive TKI that inhibits Bcr-Abl and induces apoptosis in both imatinib-sensitive and imatinib-resistant cell lines and acts synergistically with imatinib. Adaphostin also increases levels of intracellular reactive oxygen species and can stimulate apoptosis in Ph-negative malignant cells (Mow et al 2002) . An intriguing alternative is to explore the possibility of whether molecules that have been developed as inhibitors for other protein kinases and are already undergoing clinical trials might inhibit the T315I-Bcr-Abl mutant. MK-0457 (VX-680) is a potent multikinase inhibitor with activity against aurora kinases (Carter et al 2005; Shah 2006 ). The biochemical structure of MK-0457 makes it able to bind and inhibit Bcr-Abl kinase despite the presence of T315I mutation that prevents the inhibitory activity of all other kinase inhibitors tested in the clinic including imatinib, dasatinib and nilotinib. A phase I study of MK-0457 is being conducted and the preliminary analysis has shown responses in some of the patients with CML who had failed imatinib and had the T315I mutation, as well as patients with myeloproliferative disorders with the JAK-2 mutation. Phase II studies of this agent, with particular attention to these patient populations, are starting (Giles et al 2007) .
Conclusion
Since Bcr-Abl signaling remains central to CML pathogenesis, the selective inhibition of wild type and imatinib resistant Bcr-Abl signaling is still the therapeutic strategy of choice to overcome imatinib resistance. This approach led to the development of novel tyrosine kinase inhibitors more potent than imatinib, such as dasatinib and nilotinib. Preclinical and early-phase clinical fi ndings indicate that nilotinib, a "cousin" of imatinib, may be useful in the treatment of imatinib-refractory CML, due to its strong binding affi nity to Abl, its activity against imatinib-resistant BCR-ABL mutants and its effi cacy and tolerability in clinical studies. However, the durability of responses remains undefi ned. Furthermore, nilotinib (like imatinib and dasatinib) do not overcome the T315I-Bcr-Abl mutation, which may drive the majority of acquired resistance cases to these compounds. Strategies to override resistance mediated by the T315I mutation represent the next major goal in the targeted treatment of CML. Compounds such as VX-680, an aurora kinase inhibitor, capable of binding to and inhibiting kinase activity of the T315I-Bcr-Abl mutation, are very encouraging.
